LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

1.92 -3.03

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.77

Max

Schlüsselkennzahlen
By Trading Economics
Angestellte	26

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.5M 16M
Vorheriger Eröffnungskurs	4.95
Vorheriger Schlusskurs	1.92

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Nov. 2025, 22:42 UTC

Market Talk

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21. Nov. 2025, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

21. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Nov. 2025, 21:47 UTC

Market Talk

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21. Nov. 2025, 21:43 UTC

Market Talk

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21. Nov. 2025, 20:18 UTC

Market Talk

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21. Nov. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21. Nov. 2025, 19:48 UTC

Market Talk

Precious Metals Fall for the Week -- Market Talk

21. Nov. 2025, 19:44 UTC

Ergebnisse

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21. Nov. 2025, 19:37 UTC

Market Talk

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21. Nov. 2025, 19:27 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

21. Nov. 2025, 19:27 UTC

Market Talk

Ergebnisse

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21. Nov. 2025, 19:20 UTC

Market Talk

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21. Nov. 2025, 18:44 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21. Nov. 2025, 18:37 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21. Nov. 2025, 18:34 UTC

Market Talk

Ergebnisse

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21. Nov. 2025, 18:28 UTC

Ergebnisse

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21. Nov. 2025, 18:03 UTC

Market Talk

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21. Nov. 2025, 17:24 UTC

Market Talk

Global Equities Roundup: Market Talk

21. Nov. 2025, 17:24 UTC

Market Talk

Intuit Seen on Path to Increase Growth -- Market Talk

21. Nov. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Nov. 2025, 17:05 UTC

Market Talk

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21. Nov. 2025, 16:56 UTC

Market Talk

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21. Nov. 2025, 16:47 UTC

Market Talk

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21. Nov. 2025, 16:35 UTC

Akquisitionen, Fusionen, Übernahmen

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21. Nov. 2025, 16:09 UTC

Ergebnisse

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21. Nov. 2025, 15:59 UTC

Market Talk

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21. Nov. 2025, 15:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Nov. 2025, 15:23 UTC

Market Talk

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21. Nov. 2025, 15:17 UTC

Market Talk

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.